CICC International: Maintain a "buy" rating on Jiangsu Hengrui Medicine (02595) with a target price of HK$58.

According to the Wise Finance APP, China International Capital Corporation released a research report stating that it maintains a "buy" investment rating and a target price of HK$51 for Jinfan Pharmaceutical (02595). The bank stated that the overseas clinical and partnership progress of the KRAS G12D inhibitor is ideal. China International Capital Corporation believes that excellent preliminary overseas data provides further evidence of the best potential for VS7375 in its class. In the second half of 2026, Verastem will disclose more efficacy data from the TARGET-D 101 study. They recommend focusing on this. Other key overseas catalysts include: 1) completion of enrollment for the TARGET-D 101 pancreatic cancer and NSCLC monotherapy and CRC combination queues (end of June); 2) discussion with the FDA on first-line Phase III study design (end of 2026) and initiation of enrollment (first half of 2027).